Form 8-K - Current report:
SEC Accession No. 0000950170-25-083913
Filing Date
2025-06-10
Accepted
2025-06-09 17:52:09
Documents
11
Period of Report
2025-06-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250609.htm   iXBRL 8-K 76816
2 EX-4.1 tcrt-ex4_1.htm EX-4.1 20089
  Complete submission text file 0000950170-25-083913.txt   210513

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250609.xsd EX-101.SCH 28389
14 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250609_htm.xml XML 4888
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 251035291
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)